



Figure S5. NCIRPs outperforms conventional GEP biomarkers in predicting therapeutic efficacy of neoadjuvant immunotherapy in ESCC. Stacked column graphs showing the distribution of non-pCR and pCR patients across various groups based on NCIRPs, PD-L1 expression, and combination of these factors in cohort 1 (A), cohort 2 (B) and cohort 3 (C), respectively. Area under the curve (AUC) values for different gene expression signatures in cohort 1 (D), cohort 2 (E) and cohort 3 (F), respectively. Stacked column graphs illustrating the distribution of non-pCR and pCR patients across immune-enriched and risk prediction groups in cohort 1 (G), cohort 2 (H) and cohort 3 (I), respectively.